Table 1 Baseline characteristics and surgical data for patients in the landiolol and placebo groups
Characteristic | Landiolol | Placebo | Pvalue |
|---|---|---|---|
(n= 28) | (n= 28) | ||
Age, years | 68 (62–74) | 69 (60–71) | 0.36 |
Male sex | 20 (71.4) | 22 (78.6) | 0.76 |
BMI, kg/m2 | 21 (20–23) | 22 (20–23) | 0.41 |
Ejection fraction, % | 65 (60–69) | 63 (61–66) | 0.42 |
FEV1.0%, % | 75 (73–79) | 76 (71–80) | 0.47 |
eGFR, mL/min/1.73 m2 | 62 (53–73) | 66 (60–72) | 0.49 |
ASA class | |||
I | 5 (17.9) | 8 (28.6) | 0.36 |
II | 21 (75.0) | 20 (71.4) | |
III | 2 (7.1) | 0 (0.0) | |
Comorbidities | |||
Diabetes mellitus | 5 (17.9) | 2 (7.1) | 0.42 |
Hypertension | 15 (53.6) | 6 (21.4) | 0.026 |
Hyperlipidemia | 6 (21.4) | 1 (3.6) | 0.10 |
COPD | 0 (0.0) | 1 (3.6) | 1.0 |
CKD | 12 (42.9) | 7 (25.0) | 0.26 |
Dialysis | 0 (0.0) | 0 (0.0) | 1.0 |
Cerebrovascular disease | 2 (7.1) | 0 (0.0) | 0.49 |
Surgical data | |||
Surgery time, min | 442 (386–500) | 429 (402–474) | 0.93 |
Anesthesia time, min | 512 (454–568) | 501 (469–550) | 0.86 |
Anesthesia method, TIVA | 17 (60.7) | 21 (75.0) | 0.39 |
Catecholamine use | 26 (92.9) | 24 (85.7) | 0.67 |
Infusion volume, mL | 3765 (3125–4875) | 3725 (3300–4260) | 0.90 |
Transfusion volume, mL | 315 (100–400) | 340 (38–400) | 0.90 |
Urine volume, mL | 1175 (668–1456) | 965 (764–1659) | 0.58 |
Blood loss, mL | 220 (144–476) | 160 (120–303) | 0.059 |